CROWN: Persistent 7-year PFS benefits with lorlatinib versus crizotinib in advanced ALK-positive NSCLC

Lung, Respiratory and Thoracic Cancer

Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer: 7-year update from the phase 3 CROWN study

Ann Oncol

Shaw AT, Solomon BJ, Felip E, Bauer TM, Liu G, Goto Y, Wu YL, Soo RA, Mazieres J, Kim DW, Wang IM, Paolini J, Polli A, Rifi N, Toffalorio F, Mok TSK

doi: 10.1016/j.annonc.2026.05.692

ESMO 2026

Lung, Respiratory and Thoracic Cancer

CROWN: ctDNA analyses identify potential predictors of early progression with first-line lorlatinib in patients with ALK-positive NSCLC

ESMO 2026

Genitourinary Cancer

LITESPARK-011: Belzutifan plus lenvatinib maintains PFS and response benefits versus cabozantinib in advanced renal cell carcinoma

Lung, Respiratory and Thoracic Cancer

Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial

J Thorac Oncol

Baramidze A, Makharadze T, Gogishvili M, Melkadze T, Giorgadze D, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Li Y, McIntyre DAG, Jia X, Perez J, Kaul M, Lowy I, Pouliot JF, Chua S, Kim E, Seebach F, Magnan H

doi: 10.1016/j.jtho.2026.103980

ELCC 2026

Lung, Respiratory and Thoracic Cancer

LBA1: LATIFY: No survival benefit with ceralasertib plus durvalumab versus docetaxel in patients with previously treated advanced NSCLC

WCLC 2026

Lung, Respiratory and Thoracic Cancer

Actionable Genomic Alterations in NSCLC: What is Changing in Testing and Treatment?

SABCS 2025

Breast Cancer

CAPItello-291: ctDNA analyses confirm benefit of capivasertib plus fulvestrant in HR-positive advanced breast cancer

CHICAGO 2026

Lung, Respiratory and Thoracic Cancer

LBA4: HARMONi-6: Ivonescimab plus chemotherapy significantly improved OS versus tislelizumab plus chemotherapy in previously untreated advanced squamous NSCLC

WCLC 2026

Lung, Respiratory and Thoracic Cancer

Related content

Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer: 7-year update from the phase 3 CROWN study

CROWN: ctDNA analyses identify potential predictors of early progression with first-line lorlatinib in patients with ALK-positive NSCLC

LITESPARK-011: Belzutifan plus lenvatinib maintains PFS and response benefits versus cabozantinib in advanced renal cell carcinoma

Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial

LBA1: LATIFY: No survival benefit with ceralasertib plus durvalumab versus docetaxel in patients with previously treated advanced NSCLC

Actionable Genomic Alterations in NSCLC: What is Changing in Testing and Treatment?

CAPItello-291: ctDNA analyses confirm benefit of capivasertib plus fulvestrant in HR-positive advanced breast cancer

LBA4: HARMONi-6: Ivonescimab plus chemotherapy significantly improved OS versus tislelizumab plus chemotherapy in previously untreated advanced squamous NSCLC

ADAURA: Adjuvant osimertinib provides OS benefit at eight years in patients with resected EGFR-mutated NSCLC